全球人类肝臟模型市场规模、份额、趋势和成长分析报告（2026-2034年）

预计人类肝臟模型市场将从 2025 年的 21.8 亿美元成长到 2034 年的 73.2 亿美元，2026 年至 2034 年的复合年增长率为 14.38%。

随着对先进临床前试验、药物研发和个人化医疗的需求日益增长，全球人工肝臟模型市场正受到广泛关注。传统的二维培养和动物模型在模拟人类肝臟的生理功能方面存在局限性，因此人们对三维生物列印技术、晶片器官技术和干细胞衍生肝臟模型越来越感兴趣。这些技术能够更精确地模拟药物代谢、毒性和疾病进展，从而提高转化研究的成功率。

製药公司正在利用人类肝臟模型来加速药物开发平臺，最大限度地减少临床试验失败，并满足严格的安全评估监管要求。研究机构正在利用晶片肝臟平台在受控环境下研究非酒精性脂肪性肝病（NAFLD）、肝炎和肝纤维化等疾病。此外，生物列印技术和可扩展培养系统的进步正在加速高可重复性肝组织的商业性化应用。

未来，人类肝臟模型、人工智慧驱动的预测分析、高通量筛检和多器官平台的整合将重塑生物医学研究。精准医学的进步将使利用患者来源的肝臟模型进行个人化治疗试验成为可能，从而为客製化治疗通讯协定铺平道路。随着生物技术、组织工程和计算生物学的融合，这个市场有望彻底改变药物研发和疾病建模。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球人类肝臟模型市场：依产品划分

• 市场分析、洞察与预测
• 二维模型（细胞株、​​原代细胞）
• 3D模型（晶片肝臟、类器官、球状体等）

第五章：全球人类肝臟模型市场：按应用划分

• 市场分析、洞察与预测
• ADME 测试
• 毒性测试
• 疾病建模
• 其他的

第六章：全球人类肝臟模型市场：依最终用途划分

• 市场分析、洞察与预测
• 学术研究机构
• 製药和生物技术公司
• 受託研究机构

第七章 全球人类肝臟模型市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • ATCC
  • Merck KGaA
  • AcceGen
  • ZenBio Inc
  • Organovo Holdings Inc
  • BioIVT
  • InSphero
  • Emulate Inc
  • Mimetas
  • CN Bio Innovations Ltd

The Human Liver Model Market size is expected to reach USD 7.32 Billion in 2034 from USD 2.18 Billion (2025) growing at a CAGR of 14.38% during 2026-2034.

The global human liver model market is gaining traction as demand for advanced preclinical testing, drug discovery, and personalized medicine intensifies. Traditional 2D cultures and animal models face limitations in replicating human liver physiology, driving interest in 3D bioprinted, organ-on-chip, and stem cell-derived liver models. These technologies enable more accurate simulation of drug metabolism, toxicity, and disease progression, improving translational success rates.

Pharmaceutical companies are adopting human liver models to accelerate drug pipelines, minimize clinical trial failures, and comply with stringent regulatory requirements for safety evaluation. Research institutes are leveraging liver-on-chip platforms to study conditions such as nonalcoholic fatty liver disease (NAFLD), hepatitis, and fibrosis in controlled environments. Moreover, bioprinting advances and scalable culture systems are facilitating commercial deployment of highly reproducible liver tissues.

In the future, integration of human liver models with AI-driven predictive analytics, high-throughput screening, and multi-organ platforms will reshape biomedical research. As precision medicine advances, patient-derived liver models will allow individualized therapy testing, paving the way for customized treatment protocols. With growing convergence of biotechnology, tissue engineering, and computational biology, the market is poised to revolutionize drug development and disease modeling.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• 2D Models (Cell lines, Primary Cells)
• 3D Models (Liver on Chip, Organoids, Spheroids, Others)

By Application

• ADME Studies
• Toxicology Testing
• Disease Modelling
• Others

By End Use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

COMPANIES PROFILED

• ATCC, Merck KGaA, AcceGen, ZenBio Inc, Organovo Holdings Inc, BioIVT, InSphero, Emulate Inc, Mimetas, CN Bio Innovations Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN LIVER MODEL MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. 2D Models (Cell lines, Primary Cells) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. 3D Models (Liver on Chip, Organoids, Spheroids, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN LIVER MODEL MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. ADME Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Toxicology Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Disease Modelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN LIVER MODEL MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN LIVER MODEL MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN LIVER MODEL INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 ATCC
  • 9.2.2 Merck KGaA
  • 9.2.3 AcceGen
  • 9.2.4 ZenBio Inc
  • 9.2.5 Organovo Holdings Inc
  • 9.2.6 BioIVT
  • 9.2.7 InSphero
  • 9.2.8 Emulate Inc
  • 9.2.9 Mimetas
  • 9.2.10 CN Bio Innovations Ltd